Literature DB >> 23566348

BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid.

Soraia Barao1, Lujia Zhou, Katarzyna Adamczuk, Tine Vanhoutvin, Fred van Leuven, David Demedts, Anne-Catherine Vijverman, Xavier Bossuyt, Rik Vandenberghe, Bart De Strooper.   

Abstract

Previous studies have investigated the activity and protein levels of BACE1, the β-secretase, in the brain and cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients, however, results remain contradictory. We present here a highly specific and sensitive BACE1 ELISA, which allows measuring accurately BACE1 levels in human samples. We find that BACE1 levels in CSF of AD patients and other neurological disorder (OND) patients are slightly increased when compared to those of a non-neurological disorder control group (NND). BACE1 levels in CSF were well correlated with total-tau and hyperphosphorylated tau levels in the CSF, suggesting that the recorded alterations in BACE1 levels correlate with cell death and neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566348     DOI: 10.2174/15672050113109990138

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  15 in total

1.  Characterization of Cerebrospinal Fluid BACE1 Species.

Authors:  Inmaculada Lopez-Font; Claudia P Boix; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero
Journal:  Mol Neurobiol       Date:  2019-07-09       Impact factor: 5.590

2.  MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects.

Authors:  Justin M Long; Balmiki Ray; Debomoy K Lahiri
Journal:  J Biol Chem       Date:  2013-12-18       Impact factor: 5.157

Review 3.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 4.  Cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Xiaojing Sui; Jianjun Liu; Xifei Yang
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

Review 5.  Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease.

Authors:  Inmaculada Lopez-Font; Inmaculada Cuchillo-Ibañez; Aitana Sogorb-Esteve; María-Salud García-Ayllón; Javier Sáez-Valero
Journal:  Front Neurol       Date:  2015-06-02       Impact factor: 4.003

6.  CSF Presenilin-1 complexes are increased in Alzheimer's disease.

Authors:  María-Salud García-Ayllón; María-Letizia Campanari; Gunnar Brinkmalm; Alberto Rábano; Jordi Alom; Carlos A Saura; Niels Andreasen; Kaj Blennow; Javier Sáez-Valero
Journal:  Acta Neuropathol Commun       Date:  2013-08-06       Impact factor: 7.801

7.  Heteromers of amyloid precursor protein in cerebrospinal fluid.

Authors:  Inmaculada Cuchillo-Ibañez; Inmaculada Lopez-Font; Alba Boix-Amorós; Gunnar Brinkmalm; Kaj Blennow; Jose-Luis Molinuevo; Javier Sáez-Valero
Journal:  Mol Neurodegener       Date:  2015-01-08       Impact factor: 14.195

8.  The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.

Authors:  Ann De Vos; Hanne Struyfs; Dirk Jacobs; Erik Fransen; Tom Klewansky; Ellen De Roeck; Caroline Robberecht; Christine Van Broeckhoven; Charles Duyckaerts; Sebastiaan Engelborghs; Eugeen Vanmechelen
Journal:  J Alzheimers Dis       Date:  2016-07-06       Impact factor: 4.472

9.  BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.

Authors:  Maarten Timmers; Soraia Barão; Bianca Van Broeck; Ina Tesseur; John Slemmon; Katja De Waepenaert; Jennifer Bogert; Leslie M Shaw; Sebastiaan Engelborghs; Dieder Moechars; Marc Mercken; Luc Van Nueten; Luc Tritsmans; Bart de Strooper; Johannes Rolf Streffer
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.

Authors:  Rafaela Peron; Izabela Pereira Vatanabe; Patricia Regina Manzine; Antoni Camins; Márcia Regina Cominetti
Journal:  Pharmaceuticals (Basel)       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.